EP
REGN icon

Eversept Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Eversept Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,097
Closed -$7.79M – 145
2025
Q4 		$7.79M Sell
10,097
-6,623
-40% -$4.5M 0.39% 63
2025
Q3 		$9.4M Buy
16,720
+3,466
+26% +$1.96M 0.65% 37
2025
Q2 		$6.96M Buy
+13,254
New +$7.4M 0.64% 37

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Eversept Partners's REGN Position: Q1 2026 in Review

Eversept Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 10,097 shares — an estimated $7.79M sold.

Eversept Partners first reported a position in REGN in Q2 2025 and held it in 3 quarters. The position peaked at $9.4M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Eversept Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 10,097 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.79M.
  • Eversept Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Eversept Partners's Regeneron Pharmaceuticals position peaked at $9.4M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.